WBC Genetics Flashcards
t(12;21) involving RUNX1 and ETV6
B-ALL
NOTCH1 mutations
T-ALL and CLL(worse prognosis)
90% of ALLs have what numerical or structural change?
hyperploidy
TdT+
pre-lymphoblasts (B or T)
CD19
pre-B lymphoblast (B-ALL)
t(9;22) - what gene is changed and what two neoplasms result respective prognosis
Philadelphia chromosome = BCR-ABL tyrosine kinase activation (B-ALL=worse prognosis and CML=better prognosis)
Deletions of 13q14.3, 11q, 17p, and trisomy 12q
CLL/SLL
CD19, CD20, CD23, CD5
CLL/SLL
t(14;18) leading to overexpression of BCL2-IgH, which antagonizes apoptosis and promotes survival of this tumor cell (90%)
Follicular Lymphoma
MLL2 gene (90%)
Follicular Lymphoma
CD19, CD20, surface Ig, BCL6+, BCL2-
Follicular Lymphoma
BCL6+ is normal or pathologic in LN follicles?
BCL2+ is normal or pathologic in LN follicles?
Where do you assay these?
normal
pathologic
Assay them in the lymph nodes, not the peripheral blood.
BCL6+ (30%), t(14;18)=BCL2 (10%), MYC gene (5%)
Diffuse Large B-Cell Lymphoma
CD19, 20, 10, BCL6+, surface Ig
Diffuse Large B-Cell Lymphoma
t(8;14) = c-myc+ (all have this)
Burkitt Lymphoma
EBV
- Burkitt (25%)
- Immunodeficiency-associated large B-cell lymphoma
- Extranodal NK-T-cell Lymphoma
- Hodgkin Lymphoma
CD19, 20, 10, BCL6+, BCL2-
Burkitt
diverse rearrangements involving IgH, 13q deletions
Cyclin D1
Multiple myeloma